Pharmaceutical Executive
The latest news on the growing cost of conducting clinical trials is becoming a major concern for company sponsors and trial co-operative groups.
Mukhtar Ahmed
Advertisement
Mukhtar Ahmed is Vice President, Product Strategy, Oracle Health Sciences.
Articles by Mukhtar Ahmed
Mukhtaer Ahmed outlines how advances in machine-to-machine (M2M) technologies have the potential to transform clinical development programs, including clinical trials.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Bayer Shares Briefly Dip After Activist Investor Offloads Millions of Dollars in Company Stock
2
Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio
3
Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-Apnimed Sleep Science
4
FDA Sends Warning Letter to ImmunityBio for Misleading Claims in Advertisement
5